We believe that we are pioneering genuinely breakthrough technology that would change the way neuropsychiatric conditions are treated. The demonstrated clinical efficacy and excellent safety profile of our novel pherine molecules can greatly improve the treatment of numerous patients suffering acute conditions. Our goals are to bring the company’s first products, PH94B nasal spray for Social Anxiety Disorder, PH10 nasal spray for Depression and PH80-HF for Menopausal Hot Flashes through the NDA review approval process with the U.S. FDA while simultaneously continuing the development of other product candidates.

Pherin Product Candidates

PH94B - [Social Anxiety Disorder]

PH10 - [Depression]

PH80-HF - [Menopausal Hot Flashes]

PH15 - [Cognitive Improvement]

Company Overview

Pherin Pharmaceuticals, Inc. is a privately held clinical stage company headquartered in Mountain View, California, USA, focused on the development of its proprietary compounds called pherines, for the acute treatment of neuropsychiatric and neuroendocrine conditions.

Founded in 1991 and restructured in 2003, Pherin Pharmaceuticals is a clinical-stage development company led by a highly experienced senior management team. Pherin Pharmaceuticals has assembled a network of external experts to successfully bring its products through all aspects of development.

Because pherines engage receptors in the nasal passages, the drug is rapidly effective in ultra low quantities (nanograms or low micrograms) without the need of systemic exposure, providing a demonstrated rapid therapeutic onset of efficacy and an excellent safety profile with greater patient convenience.

Pherin Pharmaceuticals lead program PH94B was developed from proprietary compounds called pherines. Administered as a nasal spray, PH94B acts locally on peripheral nasal chemosensory receptors that trigger rapid activation of the limbic-hypothalamic areas of the brain associated with social anxiety disorder. This mechanism of pharmacological action, the rapid onset of efficacy, and the excellent safety and tolerability profile shown in clinical trials make PH94B an excellent product candidate for the acute treatment of patients with social anxiety.